Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 15.0
(-0.46%)
CNY 15.0
(-0.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 435.24 Million CNY | 36.4% |
| 2022 | 319.1 Million CNY | 287.54% |
| 2021 | 82.33 Million CNY | 459.62% |
| 2020 | 14.71 Million CNY | -91.08% |
| 2019 | 164.92 Million CNY | 134.82% |
| 2018 | 70.23 Million CNY | 146.44% |
| 2017 | 28.5 Million CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | -100.0% |
| 2013 | 18 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 364.11 Million CNY | 88.71% |
| 2024 Q1 | 192.94 Million CNY | -55.67% |
| 2024 Q3 | 332 Million CNY | -7.31% |
| 2023 Q1 | 404.06 Million CNY | 26.63% |
| 2023 FY | 435.24 Million CNY | 36.4% |
| 2023 Q4 | 435.24 Million CNY | 0.92% |
| 2023 Q2 | 385.58 Million CNY | -4.57% |
| 2023 Q3 | 431.26 Million CNY | 11.85% |
| 2022 Q4 | 319.1 Million CNY | 207.37% |
| 2022 FY | 319.1 Million CNY | 287.54% |
| 2022 Q3 | 103.81 Million CNY | -18.2% |
| 2022 Q1 | 82.36 Million CNY | 0.03% |
| 2022 Q2 | 126.91 Million CNY | 54.09% |
| 2021 Q3 | 60.48 Million CNY | 451.39% |
| 2021 FY | 82.33 Million CNY | 459.62% |
| 2021 Q4 | 82.33 Million CNY | 36.14% |
| 2021 Q2 | 10.96 Million CNY | -10.88% |
| 2021 Q1 | 12.3 Million CNY | -16.35% |
| 2020 FY | 14.71 Million CNY | -91.08% |
| 2020 Q4 | 14.71 Million CNY | -92.12% |
| 2020 Q2 | 186.65 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q3 | 186.76 Million CNY | 0.06% |
| 2019 Q4 | 164.92 Million CNY | 0.0% |
| 2019 FY | 164.92 Million CNY | 134.82% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | 70.23 Million CNY | 146.44% |
| 2017 FY | 28.5 Million CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2014 FY | - CNY | -100.0% |
| 2013 FY | 18 Million CNY | 0.0% |